Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Time to viral clearance 3% Improvement Relative Risk c19hcq.org An et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 226 patients in South Korea No significant difference in viral clearance An et al., medRxiv, doi:10.1101/2020.07.04.20146548 Favors HCQ Favors control
Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea
An et al., medRxiv, doi:10.1101/2020.07.04.20146548 (Preprint)
An et al., Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort.., medRxiv, doi:10.1101/2020.07.04.20146548 (Preprint)
Jul 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective of hospitalized patients with 31 HCQ patients and 195 standard treatment patients, not showing a significant difference in terms of viral clearance or recovery. There was no mortality in either group.
"It is notable that HQ plus antibiotics group had worse baseline clinical profiles (i.e. higher percentage of moderate severity patients, more patients with fever >=37.5C, higher average body temperature) and prognostic indicators such as age, LDH, lymphocyte count, and CRP".
We note that propensity score matching removed almost all of the male patients in the control group (40% -> 5%) but increased the percentage of male patients in the treatment group. This provides a large advantage to the control group because there is a very large difference in severity and mortality based on gender [ncbi.nlm.nih.gov].
In terms of viral RNA clearance we note that other research has found that "active viral replication drops quickly after the first week, and viable virus was not found after the second week of illness despite the persistence of PCR detection of RNA” [ams.edu.sg].
time to viral clearance, 3.0% lower, HR 0.97, p = 0.92, treatment 31, control 195.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
An et al., 7 Jul 2020, retrospective, South Korea, preprint, 12 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.07.04.20146548; this version posted July 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea Min Ho An, MD1,4*, Min Seo Kim, MD2,5*, Yu-Kyung Park, MD3, Bong-Ok Kim, MD, PhD3, Seok Ho Kang, MD9, PhD, Won Jun Kim, MD2, Sung Kyu Park, MD3, Hea-Woon Park, MD, PhD3, Wonjong Yang, MD3, Joonyoung Jang, MD3, Soon-Woo Jang, MD, KMD6,10, Tae-Ho Hwang, DSS, PhD7,8 *two authors contributed equally to this work 1 Ajou University, School of Medicine, Suwon, Republic of Korea 2 Korea University, College of Medicine, Seoul, Republic of Korea 3 Korea Workers’ Compensation & Welfare Services Daegu Hospital, 515 Hakjeong-ro, Buk-gu, Daegu, Republic of Korea 4 Director of So Ahn Public Health Center, Wando, Republic of Korea 5 Director of Cheongsan Public Health Center, Wando, Republic of Korea 6 Director of Bukha Public Health Center, Jangseong, Republic of Korea 7 Department of Pharmacology, Pusan National University, School of Medicine, Yangsan, Republic of Korea 8 Gene and Cell Therapy Research Center for Vessel-associated Diseases, School of Medicine, Pusan National University, Yangsan, Republic of Korea 9 Department of Urology, Korea University, School of Medicine, Seoul, Republic of Korea 10 Pusan University, School of Medicine, Yangsan, Republic of Korea Corresponding author: Soon-Woo Jang, MD, KMD6,10 Pusan University, School of Medicine, Yangsan, Republic of Korea Director of Bukha Public Health Center, Jangseong, Republic of Korea Phone : +82-10-88994593 E-mail : kmedicsoon@gmail.com Tae-Ho Hwang, DSS, PhD7,8 Department of pharmacology, Pusan National University, School of Medicine, Yangsan, Republic of Korea Director of Gene and Cell Therapy Research Center for Vessel-associated Diseases, School of Medicine, Pusan National University, Yangsan, Republic of Korea Phone: +82-10-71579950 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. E-mail : thhwang@pusan.ac.kr medRxiv preprint doi: https://doi.org/10.1101/2020.07.04.20146548; this version posted July 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Keywords: COVID-19, Hydroxychloroquine, antibiotics, azithromycin, treatment response, retrospective cohort study. Short-Running Title: Response to pharmacological treatment of COVID-19 Total word count: abstract(235), total manuscript without abstract(2411) Number of figures: 2 Number of tables: 3 Number of supplementary figures and tables: 1 Funding: The authors received no funding for this investigation Declaration of Conflicting interest The authors have no competing interests to disclose Abstract Objectives: To assess the efficacy of hydroxychloroquine on mild-moderate COVID-19 patients in South Korea. Methods: A retrospective cohort study of the 358 laboratory-confirmed SARS-CoV-2 (COVID-19) patients was conducted. 226 patients met inclusion criteria for..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit